Diagnosis and management of dysplasia in patients with ulcerative colitis and Crohn's disease of the colon

Inflammatory Bowel Diseases

Volumn 15, Issue 4, 2009, Pages 630-638

  Ullman, Thomas ^a   Odze, Robert ^b   Farraye, Francis A ^c,d  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c BOSTON UNIVERSITY MEDICAL CENTER   (United States)

^d NONE   (United States)

Author keywords

Chemoprevention; Colorectal cancer; Crohn's disease; DALM; Dysplasia; Ulcerative colitis

Indexed keywords

5 ACETAMIDOSALICYLIC ACID; FOLIC ACID; IMMUNOMODULATING AGENT; MESALAZINE; SALAZOSULFAPYRIDINE; URSODEOXYCHOLIC ACID;

CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER RISK; CHEMOPROPHYLAXIS; CHROMOENDOSCOPY; COLON ADENOMA; COLON BIOPSY; COLON CROHN DISEASE; COLON DYSPLASIA; COLON RESECTION; COLORECTAL CANCER; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DISEASE SURVEILLANCE; DYSPLASIA; ENDOSCOPIC SURGERY; FAMILY HISTORY; FLAT HIGH GRADE DYSPLASIA; FLAT LOW GRADE DYSPLASIA; HUMAN; ONSET AGE; PRIORITY JOURNAL; REVIEW; ULCERATIVE COLITIS; COLORECTAL TUMOR; CROHN DISEASE; RISK FACTOR;

COLITIS, ULCERATIVE; COLORECTAL NEOPLASMS; CROHN DISEASE; HUMANS; RISK FACTORS;

EID: 67650121080     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20766     Document Type: Review

References (87)

1. Morson BC, Pang LS. Rectal biopsy as an aid to cancer control in ulcerative colitis. Gut. 1967;8:423-434.
2. Crohn BB, Rosenberg H. The sigmoidoscopic picture of chronic ulcerative colitis. Am J Med Sci. 1925;170:220-228.
3. Weedon DD, Shorter RG, Ilstrup DM, et al. Crohn's disease and cancer. N Engl J Med. 1973;289:1099-1103.
4. Gyde SN, Prior P, Macartney JC, et al. Malignancy in Crohn's disease. Gut. 1980;21:1024-1029.
5. Persson PG, Karlen P, Bernell O, et al. Crohn's disease and cancer: a population-based cohort study. Gastroenterology. 1994;107:1675-1679.
6. Gillen CD, Andrews HA, Prior P, et al. Crohn's disease and colorectal cancer. Gut. 1994;35:651-655.
7. Ekbom A, Helmick C, Zack M, et al. Increased risk of large-bowel cancer in Crohn's disease with colonic involvement. Lancet. 1990;336: 357-359.
8. Gillen CD, Walmsley RS, Prior P, et al. Ulcerative colitis and Crohn's disease: a comparison of the colorectal cancer risk in extensive colitis. Gut. 1994;35:1590-1592.
9. Sachar DB. Cancer in Crohn's disease: dispelling the myths. Gut. 1994;35:1507-1508.
10. Munkholm P, Langholz E, Davidsen M, et al. Intestinal cancer risk and mortality in patients with Crohn's disease. Gastroenterology. 1993;105: 1716-1723.
11. Bernstein CN, Blanchard JF, Kliewer E, et al. Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer. 2001;91:854-862.
12. Canavan C, Abrams KR, Mayberry J. Meta-analysis: colorectal and small bowel cancer risk in patients with Crohn's disease. Aliment Pharmacol Ther. 2006;23:1097-1104.
13. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 2001;48:526-535.
14. Jess T, Loftus EV Jr, Velayos FS, et al. Incidence and prognosis of colorectal dysplasia in inflammatory bowel disease: a population-based study from Olmsted County, Minnesota. Inflamm Bowel Dis. 2006;12: 669-676.
15. Masala G, Bagnoli S, Ceroti M, et al. Divergent patterns of total and cancer mortality in ulcerative colitis and Crohn's disease patients: the Florence IBD study 1978-2001. Gut. 2004;53:1309-1313.
16. Lakatos L, Mester G, Erdelyi Z, et al. Risk factors for ulcerative colitis-associated colorectal cancer in a Hungarian cohort of patients with ulcerative colitis: results of a population-based study. Inflamm Bowel Dis. 2006;12:205-211.
17. Rutter MD, Saunders BP, Wilkinson KH, et al. Thirty-year analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis. Gastroenterology. 2006;130:1030-1038.
18. Itzkowitz SH, Present DH. Consensus conference: Colorectal cancer screening and surveillance in inflammatory bowel disease. Inflamm Bowel Dis. 2005;11:314-321.
19. Eaden JA, Mayberry JF. Guidelines for screening and surveillance of asymptomatic colorectal cancer in patients with inflammatory bowel disease. Gut. 2002;51:V10-V12.
20. Ekbom A, Helmick C, Zack M, et al. Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med. 1990; 323:1228-1233.
21. Friedman S, Rubin PH, Bodian C, et al. Screening and surveillance colonoscopy in chronic Crohn's colitis. Gastroenterology. 2001;120: 820-826.
22. Itzkowitz SH, Harpaz N. Diagnosis and management of dysplasia in patients with inflammatory bowel diseases. Gastroenterology. 2004;126: 1634-1648.
23. Nuako KW, Ahlquist DA, Mahoney DW, et al. Familial predisposition for colorectal cancer in chronic ulcerative colitis: a case-control study. Gastroenterology. 1998;115:1079-1083.
24. Gupta RB, Harpaz N, Itzkowitz S, et al. Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology. 2007;133:1099-1105; quiz 1340-1341.
25. Rutter M, Saunders B, Wilkinson K, et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology. 2004;126:451-459.
26. Haskell H, Andrews CW Jr, Reddy SI, et al. Pathologic features and clinical significance of "backwash" ileitis in ulcerative colitis. Am J Surg Pathol. 2005;29:1472-1481.
27. Heuschen UA, Hinz U, Allemeyer EH, et al. Backwash ileitis is strongly associated with colorectal carcinoma in ulcerative colitis. Gastroenterology. 2001;120:841-847.
28. Collins PD, Mpofu C, Watson AJ, et al. Strategies for detecting colon cancer and/or dysplasia in patients with inflammatory bowel disease. Cochrane Database Syst Rev. 2006:CD000279.
29. Rubin CE, Haggitt RC, Burmer GC, et al. DNA aneuploidy in colonic biopsies predicts future development of dysplasia in ulcerative colitis. Gastroenterology. 1992;103:1611-1620.
30. Eaden JA, Ward BA, Mayberry JF. How gastroenterologists screen for colonic cancer in ulcerative colitis: an analysis of performance. Gastrointest Endosc. 2000;51:123-128.
31. Ullman TA, Croog V, Harpaz N, et al. Biopsy specimen numbers in the routine practice of surveillance colonoscopy in ulcerative colitis (UC). Gastroenterology. 2004;126:A-471.
32. Rodriguez SA, Eisen GM. Surveillance and management of dysplasia in ulcerative colitis by U.S. gastroenterologists: in truth, a good performance. Gastrointest Endosc. 2007;66:1070.
33. Rubin DT, Rothe JA, Hetzel JT, et al. Are dysplasia and colorectal cancer endoscopically visible in patients with ulcerative colitis? Gastrointest Endosc. 2007;65:998-1004.
34. Hurlstone DP, Sanders DS, Lobo AJ, et al. Indigo carmine-assisted high-magnification chromoscopic colonoscopy for the detection and characterisation of intraepithelial neoplasia in ulcerative colitis: a prospective evaluation. Endoscopy. 2005;37:1186-1192.
35. Kiesslich R, Fritsch J, Holtmann M, et al. Methylene blue-aided chromoendoscopy for the detection of intraepithelial neoplasia and colon cancer in ulcerative colitis. Gastroenterology. 2003;124:880-888.
36. Rutter MD, Saunders BP, Schofield G, et al. Pancolonic indigo carmine dye spraying for the detection of dysplasia in ulcerative colitis. Gut. 2004;53:256-260.
37. Marion JF, Waye JD, Present DH, et al. Methylene blue spray targeted biopsies are superior to standard colonoscopic surveillance for detecting dysplasia in inflammatory bowel disease patients: a prospective endoscopic trial. Am J Gastroenterol. 2008;103:2342-2349.
38. Matsumoto T, Iwao Y, Igarashi M, et al. Endoscopic and chromoendoscopic atlas featuring dysplastic lesions in surveillance colonoscopy for patients with long-standing ulcerative colitis. Inflamm Bowel Dis. 2008; 14:259-264.
39. Dekker E, van den Broek FJ, Reitsma JB, et al. Narrow-band imaging compared with conventional colonoscopy for the detection of dysplasia in patients with longstanding ulcerative colitis. Endoscopy. 2007;39: 216-221.
40. Hurlstone DP, Kiesslich R, Thomson M, et al. Confocal chromoscopic endomicroscopy is superior to chromoscopy alone for the detection and characterisation of intraepithelial neoplasia in chronic ulcerative colitis. Gut. 2008;57:196-204.
41. Riddell RH, Goldman H, Ransohoff DF, et al. Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. Hum Pathol. 1983;14:931-968.
42. Eaden J, Abrams K, McKay H, et al. Inter-observer variation between general and specialist gastrointestinal pathologists when grading dysplasia in ulcerative colitis. J Pathol. 2001;194:152-157.
43. Dixon MF, Brown LJ, Gilmour HM, et al. Observer variation in the assessment of dysplasia in ulcerative colitis. Histopathology. 1988;13: 385-397.
44. Melville DM, Jass JR, Morson BC, et al. Observer study of the grading of dysplasia in ulcerative colitis: comparison with clinical outcome. Hum Pathol. 1989;20:1008-1014.
45. Odze RD, Goldblum J, Noffsinger A, et al. Interobserver variability in the diagnosis of ulcerative colitis-associated dysplasia by telepathology. Mod Pathol. 2002;15:379-386.
46. Connell WR, Lennard-Jones JE, Williams CB, et al. Factors affecting the outcome of endoscopic surveillance for cancer in ulcerative colitis [see comments]. Gastroenterology. 1994;107:934-944.
47. Winawer S, Fletcher R, Rex D, et al. Colorectal cancer screening and surveillance: clinical guidelines and rationale-Update based on new evidence. Gastroenterology. 2003;124:544-560.
48. Lennard-Jones JE, Morson BC, Ritchie JK, et al. Cancer surveillance in ulcerative colitis. Experience over 15 years. Lancet. 1983;2:149-152.
49. Lynch DA, Lobo AJ, Sobala GM, et al. Failure of colonoscopic surveillance in ulcerative colitis [see comments]. Gut. 1993;34:1075-1080.
50. Woolrich AJ, DaSilva MD, Korelitz BI. Surveillance in the routine management of ulcerative colitis: the predictive value of low-grade dysplasia [see comments]. Gastroenterology. 1992;103:431-438.
51. Ullman TA, Loftus EV Jr, Kakar S, et al. The fate of low grade dysplasia in ulcerative colitis. Am J Gastroenterol. 2002;97:922-927.
52. Blackstone MO, Riddell RH, Rogers BH, et al. Dysplasia-associated lesion or mass (DALM) detected by colonoscopy in long-standing ulcerative colitis: an indication for colectomy. Gastroenterology. 1981; 80:366-374.
53. Friedman S, Odze RD, Farraye FA. Management of neoplastic polyps in inflammatory bowel disease. Inflamm Bowel Dis. 2003;9:260-266.
54. Rutter MD, Saunders BP, Wilkinson KH, et al. Most dysplasia in ulcerative colitis is visible at colonoscopy. Gastrointest Endosc. 2004; 60:334-339.
55. Nugent FW, Haggitt RC, Gilpin PA. Cancer surveillance in ulcerative colitis. Gastroenterology. 1991;100:1241-1248.
56. Medlicott SA, Jewell LD, Price L, et al. Conservative management of small adenomata in ulcerative colitis. Am J Gastroenterol. 1997;92: 2094-2098.
57. Engelsgjerd M, Farraye FA, Odze RD. Polypectomy may be adequate treatment for adenoma-like dysplastic lesions in chronic ulcerative colitis. Gastroenterology. 1999;117:1288 -1294; discussion 1488-1491.
58. Odze RD, Farraye FA, Hecht JL, et al. Long-term follow-up after polypectomy treatment for adenoma-like dysplastic lesions in ulcerative colitis. Clin Gastroenterol Hepatol. 2004;2:534-541.
59. Rubin PH, Friedman S, Harpaz N, et al. Colonoscopic polypectomy in chronic colitis: conservative management after endoscopic resection of dysplastic polyps. Gastroenterology. 1999;117:1295-1300.
60. Vieth M, Behrens H, Stolte M. Sporadic adenoma in ulcerative colitis: endoscopic resection is an adequate treatment. Gut. 2006;55:1151-1155.
61. Farraye FA, Waye JD, Moscandrew M, et al. Variability in the diagnosis and management of adenoma-like and non-adenoma-like dysplasia-associated lesions or masses in inflammatory bowel disease: an Internet-based study. Gastrointest Endosc. 2007;66:519 -529.
62. Bernstein CN, Shanahan F, Weinstein WM. Are we telling patients the truth about surveillance colonoscopy in ulcerative colitis? [see comments]. Lancet. 1994;343:71-74.
63. Connell WR, Talbot IC, Harpaz N, et al. Clinicopathological characteristics of colorectal carcinoma complicating ulcerative colitis. Gut. 1994; 35:1419 -1423.
64. Lim CH, Axon AT. Low-grade dysplasia: nonsurgical treatment. Inflamm Bowel Dis. 2003;9:270 -272; discussion 273-275.
65. Befrits R, Ljung T, Jaramillo E, et al. Low-grade dysplasia in extensive, long-standing inflammatory bowel disease: a follow-up study. Dis Colon Rectum. 2002;45:615- 620.
66. Lindberg B, Persson B, Veress B, et al. Twenty years' colonoscopic surveillance of patients with ulcerative colitis. Detection of dysplastic and malignant transformation. Scand J Gastroenterol. 1996;31:1195-1204.
67. Ullman T, Croog V, Harpaz N, et al. Progression of flat low-grade dysplasia to advanced neoplasia in patients with ulcerative colitis. Gastroenterology. 2003;125:1311-1319.
68. Thomas T, Abrams KA, Robinson RJ, et al. Meta-analysis: cancer risk of low-grade dysplasia in chronic ulcerative colitis. Aliment Pharmacol Ther. 2007;25:657-668.
69. Levi GS, Harpaz N. Intestinal low-grade tubuloglandular adenocarcinoma in inflammatory bowel disease. Am J Surg Pathol. 2006; 30:1022-1029.
70. Odze RD. Pathology of dysplasia and cancer in inflammatory bowel disease. Gastroenterol Clin North Am. 2006;35:533-552.
71. Nugent FW, Haggitt RC, Gilpin PA. Cancer surveillance in ulcerative colitis [see comments]. Gastroenterology. 1991;100:1241-1248.
72. Ullman TA, Croog V, Harpaz N, et al. Progression to colorectal neoplasia in ulcerative colitis: effect of 5-aminosalicylic acid. Clin Gastroenterol Hepatol. 2008; in press.
73. Chan EP, Lichtenstein GR. Chemoprevention: risk reduction with medical therapy of inflammatory bowel disease. Gastroenterol Clin North Am. 2006;35:675-712.
74. Levine JS, Burakoff R. Chemoprophylaxis of colorectal cancer in inflammatory bowel disease: current concepts. Inflamm Bowel Dis. 2007; 13:1293-1298.
75. Lashner BA, Heidenreich PA, Su GL, et al. Effect of folate supplementation on the incidence of dysplasia and cancer in chronic ulcerative colitis. A case-control study [see comments]. Gastroenterology. 1989; 97:255-259.
76. Eaden J, Abrams K, Ekbom A, et al. Colorectal cancer prevention in ulcerative colitis: a case-control study. Aliment Pharmacol Ther. 2000; 14:145-153.
77. Pinczowski D, Ekbom A, Baron J, et al. Risk factors for colorectal cancer in patients with ulcerative colitis: a case-control study. Gastroenterology. 1994;107:117-120.
78. Tung BY, Emond MJ, Haggitt RC, et al. Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Ann Intern Med. 2001;134:89-95.
79. van Staa TP, Card T, Logan RF, et al. 5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study. Gut. 2005;54:1573-1578.
80. Rubin DT, LoSavio A, Yadron N, et al. Aminosalicylate therapy in the prevention of dysplasia and colorectal cancer in ulcerative colitis. Clin Gastroenterol Hepatol. 2006;4:1346-1350.
81. Bernstein CN, Blanchard JF, Metge C, et al. Does the use of 5-aminosalicylates in inflammatory bowel disease prevent the development of colorectal cancer? Am J Gastroenterol. 2003;98:2784-2788.
82. Terdiman JP, Steinbuch M, Blumentals WA, et al. 5-Aminosalicylic acid therapy and the risk of colorectal cancer among patients with inflammatory bowel disease. Inflamm Bowel Dis. 2007;13:367-371.
83. Velayos FS, Terdiman JP, Walsh JM. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and meta-analysis of observational studies. Am J Gastroenterol. 2005;100:1345-1353.
84. Lashner BA, Provencher KS, Seidner DL, et al. The effect of folic acid supplementation on the risk for cancer or dysplasia in ulcerative colitis. Gastroenterology. 1997;112:29-32.
85. Pardi DS, Loftus EV Jr, Kremers WK, et al. Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology. 2003;124:889-893.
86. Matula S, Croog V, Itzkowitz S, et al. Chemoprevention of colorectal neoplasia in ulcerative colitis: the effect of 6-mercaptopurine. Clin Gastroenterol Hepatol. 2005;3:1015-1021.
87. Mpofu C, Watson AJ, Rhodes JM. Strategies for detecting colon cancer and/ or dysplasia in patients with inflammatory bowel disease. Cochrane Database Syst Rev. 2004:CD000279.